Ovarian cancer, predominantly epithelial, is the ninth most common and fifth most lethal cancer among women in France, with late diagnosis and poor prognosis despite curative treatments. The KELIM model, built according to Ca125 kinetics, given its proven predictive and prognostic characteristics, has been implemented online to aid therapeutic decision-making.

This study assessed the use of the KELIM score among French gynecological oncology experts using a survey sent from 13 December 2023 to 30 January 2024, through Google forms to all member of French Society of Gynecological Oncology (SFOG), Young of French Society of Gynecological Oncology (SFOG campus) and National Investigators Group for Ovarian and Breast Cancer Studies in France (GINECO-ARCAGY).

Fifty-two respondents, mainly gynecology and medical oncologists, revealed that 58% of them have used KELIM score, primarily in neoadjuvant settings. Participants considered that the KELIM score was mainly used to define the chemosensitivity (79%) and to identify patients who could then receive bevacizumab (82%). In the maintenance setting, the KELIM score was reported as quite frequently used (41%). It was inconsistently used to help the surgical procedure decision (37%).

The KELIM score predictive value for chemosensitivity, is acknowledged, especially for bevacizumab indications. However, its adoption into routine practice is dependent on the level of familiarity of practitioners. The findings suggest that while KELIM is seen as a potential useful tool for reinforcing therapeutic strategies, including choice of maintenance therapy or sequence of cytoreduction surgery, its broader adoption requires enhanced education and prospective validation.